Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Ceskoslovenska Patologie|November 22, 2016
Clear cell sarcoma of vulva. A case reportKristýna Němejcová, Pavel Dundr, Ivana Krajsová
Anticancer Research|October 28, 2015
Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with MelanomaIvana Krajsová, Petr Arenberger, Radek Lakomý, et al.
International Journal of Molecular Sciences|July 20, 2021
The Abscopal Effect in the Era of Checkpoint InhibitorsOndřej Kodet, Kristýna Němejcova, Karolína Strnadová, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 13, 2013
Cultivation-dependent plasticity of melanoma phenotypeOndřej Kodet, Barbora Dvořánková, Eliška Krejčí, et al.
International Journal of Molecular Medicine|February 3, 2018
Microenvironment‑driven resistance to B‑Raf inhibition in a melanoma patient is accompanied by broad changes of gene methylation and expression in distal fibroblastsOndřej Kodet, Barbora Dvořánková, Běla Bendlová, et al.
Oncology Reports|September 24, 2019
Serum proteomic analysis of melanoma patients with immunohistochemical profiling of primary melanomas and cultured cells: Pilot studyJan Kučera, Karolína Strnadová, Barbora Dvořánková, et al.
Cancers|June 2, 2021
A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)Victoria G Atkinson, Pietro Quaglino, Massimo Aglietta, et al.
Future Oncology (London, England)|June 13, 2023
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAFReinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2022
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant MelanomaReinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2024
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanomaDirk Schadendorf, Reinhard Dummer, Keith T Flaherty, et al.
Pageof 2